<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="9" family="AdvC2866" color="#000000"/>
	<fontspec id="font1" size="9" family="AdvPS586B" color="#000000"/>
	<fontspec id="font2" size="9" family="AdvTimes" color="#000000"/>
	<fontspec id="font3" size="10" family="AdvSMyr-SB" color="#000000"/>
	<fontspec id="font4" size="6" family="AdvC2866" color="#000000"/>
	<fontspec id="font5" size="9" family="AdvC2870" color="#000000"/>
	<fontspec id="font6" size="9" family="AdvPSMP13" color="#000000"/>
	<fontspec id="font7" size="9" family="AdvC2867" color="#000000"/>
	<fontspec id="font8" size="9" family="AdvP586D" color="#000000"/>
	<fontspec id="font9" size="9" family="AdvP641C" color="#000000"/>
	<fontspec id="font10" size="9" family="AdvPSMy-B" color="#000000"/>
	<fontspec id="font11" size="9" family="AdvPSMy-R" color="#000000"/>
	<fontspec id="font12" size="8" family="AdvPSMy-B" color="#000000"/>
	<fontspec id="font13" size="7" family="AdvPSMy-R" color="#000000"/>
	<fontspec id="font14" size="7" family="AdvPSMP13" color="#000000"/>
	<fontspec id="font15" size="6" family="AdvPSMy-R" color="#000000"/>
	<fontspec id="font16" size="8" family="AdvPSMy-R" color="#000000"/>
<text top="169" left="45" width="243" height="8" font="font0" id="p1_t1" reading_order_no="20" segment_no="8" tag_type="text">safety data reports as the trial progressed and the data analysis</text>
<text top="180" left="45" width="243" height="8" font="font0" id="p1_t2" reading_order_no="21" segment_no="8" tag_type="text">by Statistics Collaborative after study completion. DSMB</text>
<text top="191" left="45" width="243" height="8" font="font0" id="p1_t3" reading_order_no="22" segment_no="8" tag_type="text">membership included a statistician and four senior clinical</text>
<text top="202" left="45" width="243" height="8" font="font0" id="p1_t4" reading_order_no="23" segment_no="8" tag_type="text">research investigators with experience in conducting malaria</text>
<text top="213" left="45" width="243" height="8" font="font0" id="p1_t5" reading_order_no="24" segment_no="8" tag_type="text">vaccine trials, one of whom was a Kenyan. An experienced</text>
<text top="224" left="45" width="243" height="8" font="font0" id="p1_t6" reading_order_no="25" segment_no="8" tag_type="text">local clinician (Ambrose Misore, M.B.Ch.B.) served as the local</text>
<text top="235" left="45" width="243" height="8" font="font0" id="p1_t7" reading_order_no="26" segment_no="8" tag_type="text">medical monitor (LMM), reviewed all serious adverse events</text>
<text top="246" left="45" width="243" height="8" font="font0" id="p1_t8" reading_order_no="27" segment_no="8" tag_type="text">(SAEs) and safety data between dose escalations, and</text>
<text top="257" left="45" width="243" height="8" font="font0" id="p1_t9" reading_order_no="28" segment_no="8" tag_type="text">functioned as the patient advocate. In addition, the trial was</text>
<text top="269" left="45" width="243" height="8" font="font0" id="p1_t10" reading_order_no="29" segment_no="8" tag_type="text">monitored for regulatory compliance by representatives of</text>
<text top="280" left="45" width="243" height="8" font="font0" id="p1_t11" reading_order_no="30" segment_no="8" tag_type="text">the United States Army Medical Materiel Development</text>
<text top="291" left="45" width="243" height="8" font="font0" id="p1_t12" reading_order_no="31" segment_no="8" tag_type="text">Activity, GlaxoSmithKline Biologicals, and Pharmaceuticals</text>
<text top="302" left="45" width="243" height="8" font="font0" id="p1_t13" reading_order_no="32" segment_no="8" tag_type="text">Product Development (a contract research organization based</text>
<text top="313" left="45" width="243" height="8" font="font0" id="p1_t14" reading_order_no="33" segment_no="8" tag_type="text">in Wilmington, North Carolina, United States), all of whom</text>
<text top="324" left="45" width="243" height="8" font="font0" id="p1_t15" reading_order_no="34" segment_no="8" tag_type="text">made several visits to the study site. Initial approval of the</text>
<text top="335" left="45" width="243" height="8" font="font0" id="p1_t16" reading_order_no="35" segment_no="8" tag_type="text">study protocol and of subsequent protocol amendments was</text>
<text top="346" left="45" width="243" height="8" font="font0" id="p1_t17" reading_order_no="36" segment_no="8" tag_type="text">granted to the investigators by the Ethical Review Committee</text>
<text top="357" left="45" width="243" height="8" font="font0" id="p1_t18" reading_order_no="37" segment_no="8" tag_type="text">of the Kenya Medical Research Institute, Nairobi; by the</text>
<text top="369" left="45" width="243" height="8" font="font0" id="p1_t19" reading_order_no="38" segment_no="8" tag_type="text">Human Subjects Protection Committee of PATH, Seattle,</text>
<text top="380" left="45" width="243" height="8" font="font0" id="p1_t20" reading_order_no="39" segment_no="8" tag_type="text">Washington, United States; and by the United States Army</text>
<text top="391" left="45" width="243" height="8" font="font0" id="p1_t21" reading_order_no="40" segment_no="8" tag_type="text">HSRRB. The study was done under a Food and Drug</text>
<text top="402" left="45" width="243" height="8" font="font0" id="p1_t22" reading_order_no="41" segment_no="8" tag_type="text">Administration IND and was compliant with all relevant</text>
<text top="413" left="45" width="223" height="8" font="font0" id="p1_t23" reading_order_no="42" segment_no="8" tag_type="text">International Conference on Harmonization guidelines.</text>
<text top="424" left="54" width="234" height="8" font="font0" id="p1_t24" reading_order_no="43" segment_no="10" tag_type="text">Vaccinations of the second and third cohorts were staggered</text>
<text top="435" left="45" width="243" height="8" font="font0" id="p1_t25" reading_order_no="44" segment_no="10" tag_type="text">from each other by 2 wk (Table 2). A safety report was produced</text>
<text top="446" left="45" width="243" height="8" font="font0" id="p1_t26" reading_order_no="45" segment_no="10" tag_type="text">prior to each dose escalation. The LMM and the DSMB reviewed</text>
<text top="457" left="45" width="243" height="8" font="font0" id="p1_t27" reading_order_no="46" segment_no="10" tag_type="text">all adverse events (AEs) occurring in the 7 d immediately</text>
<text top="468" left="45" width="243" height="8" font="font0" id="p1_t28" reading_order_no="47" segment_no="10" tag_type="text">following any vaccination that preceded a dose escalation.</text>
<text top="480" left="45" width="243" height="8" font="font0" id="p1_t29" reading_order_no="48" segment_no="10" tag_type="text">Written approval from the LMM and concurrence by the DSMB</text>
<text top="491" left="45" width="214" height="8" font="font0" id="p1_t30" reading_order_no="49" segment_no="10" tag_type="text">were required prior to any subsequent dose escalation.</text>
<text top="502" left="54" width="234" height="8" font="font0" id="p1_t31" reading_order_no="50" segment_no="12" tag_type="text">Stopping rules were to be invoked when either of the following</text>
<text top="512" left="45" width="243" height="9" font="font0" id="p1_t32" reading_order_no="51" segment_no="12" tag_type="text">observations was made: (1) . 20% of subjects with ‘‘ severe ’’</text>
<text top="524" left="45" width="243" height="8" font="font0" id="p1_t33" reading_order_no="52" segment_no="12" tag_type="text">(grade 3) general AEs (not local AEs) related to the vaccine; or (2)</text>
<text top="535" left="45" width="211" height="8" font="font0" id="p1_t34" reading_order_no="53" segment_no="12" tag_type="text">any SAE, including death, judged to be vaccine related.</text>
<text top="553" left="45" width="47" height="10" font="font3" id="p1_t35" reading_order_no="54" segment_no="14" tag_type="title">Objectives</text>
<text top="566" left="45" width="243" height="8" font="font0" id="p1_t36" reading_order_no="55" segment_no="16" tag_type="text">The primary objective was to assess the safety and reactoge-</text>
<text top="577" left="45" width="243" height="8" font="font0" id="p1_t37" reading_order_no="56" segment_no="16" tag_type="text">nicity of the FMP1/AS02A malaria vaccine in malaria-exposed</text>
<text top="588" left="45" width="243" height="8" font="font0" id="p1_t38" reading_order_no="57" segment_no="16" tag_type="text">12- to 47-mo-old children living in western Kenya. The</text>
<text top="599" left="45" width="243" height="8" font="font0" id="p1_t39" reading_order_no="58" segment_no="16" tag_type="text">secondary objective was to assess the humoral immune</text>
<text top="610" left="45" width="243" height="8" font="font0" id="p1_t40" reading_order_no="59" segment_no="16" tag_type="text">response to the FMP1/AS02A malaria vaccine in malaria-</text>
<text top="621" left="45" width="232" height="8" font="font0" id="p1_t41" reading_order_no="60" segment_no="16" tag_type="text">exposed 12- to 47-mo-old children living in western Kenya.</text>
<text top="639" left="45" width="46" height="10" font="font3" id="p1_t42" reading_order_no="61" segment_no="17" tag_type="title">Outcomes</text>
<text top="652" left="45" width="243" height="8" font="font0" id="p1_t43" reading_order_no="62" segment_no="18" tag_type="text">The primary endpoints were (1) occurrence of solicited</text>
<text top="663" left="45" width="243" height="8" font="font0" id="p1_t44" reading_order_no="63" segment_no="18" tag_type="text">symptoms (based on a standardized questionnaire) during a</text>
<text top="674" left="45" width="243" height="8" font="font0" id="p1_t45" reading_order_no="64" segment_no="18" tag_type="text">7-d follow-up period after each vaccination (postvaccination</text>
<text top="685" left="45" width="243" height="8" font="font0" id="p1_t46" reading_order_no="65" segment_no="18" tag_type="text">clinic visits occurred on study days 1, 2, 3, and 7 after each</text>
<text top="696" left="45" width="243" height="8" font="font0" id="p1_t47" reading_order_no="66" segment_no="18" tag_type="text">vaccination); (2) occurrence of unsolicited symptoms during a</text>
<text top="707" left="45" width="243" height="8" font="font0" id="p1_t48" reading_order_no="67" segment_no="18" tag_type="text">30-d follow-up period after each vaccination; and (3)</text>
<text top="719" left="45" width="243" height="8" font="font0" id="p1_t49" reading_order_no="68" segment_no="18" tag_type="text">occurrence of SAEs during an 8-mo follow-up period</text>
<text top="50" left="306" width="243" height="8" font="font0" id="p1_t50" reading_order_no="69" segment_no="2" tag_type="text">following the ﬁrst dose of study vaccine (i.e., 6 mo following</text>
<text top="61" left="306" width="243" height="8" font="font0" id="p1_t51" reading_order_no="70" segment_no="2" tag_type="text">the last vaccination). The secondary endpoints were anti-</text>
<text top="72" left="306" width="243" height="9" font="font0" id="p1_t52" reading_order_no="71" segment_no="2" tag_type="text">FMP1 (anti-MSP-1 42 3D7 strain antibody) titers as determined</text>
<text top="83" left="306" width="243" height="8" font="font0" id="p1_t53" reading_order_no="72" segment_no="2" tag_type="text">by an enzyme-linked immunosorbent assay (ELISA) on study</text>
<text top="94" left="306" width="188" height="8" font="font0" id="p1_t54" reading_order_no="73" segment_no="2" tag_type="text">days 0, 14, 30, 44, 60, 74, 90, 180, 270, and 364.</text>
<text top="105" left="315" width="234" height="8" font="font5" id="p1_t55" reading_order_no="74" segment_no="6" tag_type="text">Assessment of primary endpoints (safety and reactogenicity).</text>
<text top="116" left="306" width="243" height="8" font="font0" id="p1_t56" reading_order_no="75" segment_no="6" tag_type="text">Following each vaccination, subjects were followed for</text>
<text top="127" left="306" width="243" height="8" font="font0" id="p1_t57" reading_order_no="76" segment_no="6" tag_type="text">occurrence of solicited symptoms for 7 d, unsolicited</text>
<text top="138" left="306" width="243" height="8" font="font0" id="p1_t58" reading_order_no="77" segment_no="6" tag_type="text">symptoms for 30 d, and SAEs for 8 mo (i.e., 6 mo after the</text>
<text top="149" left="306" width="243" height="8" font="font0" id="p1_t59" reading_order_no="78" segment_no="6" tag_type="text">last vaccination) or until resolution. Both local (injection-site</text>
<text top="160" left="306" width="243" height="8" font="font0" id="p1_t60" reading_order_no="79" segment_no="6" tag_type="text">pain and swelling) and general/systemic (fever, drowsiness,</text>
<text top="171" left="306" width="243" height="8" font="font0" id="p1_t61" reading_order_no="80" segment_no="6" tag_type="text">loss of appetite, and irritability/fussiness) symptoms were</text>
<text top="182" left="306" width="243" height="8" font="font0" id="p1_t62" reading_order_no="81" segment_no="6" tag_type="text">assessed (Table 3). After the ﬁnal vaccination, subjects were</text>
<text top="193" left="306" width="243" height="8" font="font0" id="p1_t63" reading_order_no="82" segment_no="6" tag_type="text">followed monthly at home by ﬁeld workers and were asked to</text>
<text top="204" left="306" width="243" height="8" font="font0" id="p1_t64" reading_order_no="83" segment_no="6" tag_type="text">return to the clinic every 3 mo until the end of the study for</text>
<text top="215" left="306" width="243" height="8" font="font0" id="p1_t65" reading_order_no="84" segment_no="6" tag_type="text">safety follow-up. An SAE was deﬁned as any untoward</text>
<text top="226" left="306" width="243" height="8" font="font0" id="p1_t66" reading_order_no="85" segment_no="6" tag_type="text">medical occurrence that resulted in death, was life threat-</text>
<text top="237" left="306" width="243" height="8" font="font0" id="p1_t67" reading_order_no="86" segment_no="6" tag_type="text">ening, resulted in persistent or signiﬁcant disability or</text>
<text top="248" left="306" width="243" height="8" font="font0" id="p1_t68" reading_order_no="87" segment_no="6" tag_type="text">incapacity, or required in-patient hospitalization (or prolon-</text>
<text top="259" left="306" width="243" height="8" font="font0" id="p1_t69" reading_order_no="88" segment_no="6" tag_type="text">gation of hospitalization). Important medical events that</text>
<text top="270" left="306" width="243" height="8" font="font0" id="p1_t70" reading_order_no="89" segment_no="6" tag_type="text">might jeopardize a subject or might require intervention to</text>
<text top="281" left="306" width="243" height="8" font="font0" id="p1_t71" reading_order_no="90" segment_no="6" tag_type="text">prevent one of the other outcomes listed above were</text>
<text top="292" left="306" width="243" height="8" font="font0" id="p1_t72" reading_order_no="91" segment_no="6" tag_type="text">considered SAEs. Serum creatinine, ALT, white blood cell</text>
<text top="303" left="306" width="243" height="8" font="font0" id="p1_t73" reading_order_no="92" segment_no="6" tag_type="text">count, lymphocyte count, platelet count, and hemoglobin</text>
<text top="314" left="306" width="243" height="8" font="font0" id="p1_t74" reading_order_no="93" segment_no="6" tag_type="text">were determined on study days 0, 14, 30, 44, 60, 74, and 90.</text>
<text top="325" left="306" width="243" height="8" font="font0" id="p1_t75" reading_order_no="94" segment_no="6" tag_type="text">Additional hemoglobin determinations were made on study</text>
<text top="336" left="306" width="243" height="8" font="font0" id="p1_t76" reading_order_no="95" segment_no="6" tag_type="text">days 180, 270, and 364. Normal ranges were calculated on the</text>
<text top="347" left="306" width="235" height="8" font="font0" id="p1_t77" reading_order_no="96" segment_no="6" tag_type="text">basis of previous data from the local pediatric population.</text>
<text top="358" left="315" width="234" height="8" font="font5" id="p1_t78" reading_order_no="97" segment_no="9" tag_type="text">Assessment of malaria. A peripheral blood smear was</text>
<text top="369" left="306" width="243" height="8" font="font0" id="p1_t79" reading_order_no="98" segment_no="9" tag_type="text">obtained from any subject who presented to the Walter Reed</text>
<text top="380" left="306" width="243" height="8" font="font0" id="p1_t80" reading_order_no="99" segment_no="9" tag_type="text">Project’s Kombewa Clinic with fever, a history of fever within</text>
<text top="391" left="306" width="243" height="8" font="font0" id="p1_t81" reading_order_no="100" segment_no="9" tag_type="text">48 h, or an illness that the attending doctor suspected might</text>
<text top="402" left="306" width="243" height="8" font="font0" id="p1_t82" reading_order_no="101" segment_no="9" tag_type="text">be due to malaria infection. After Giemsa staining and</text>
<text top="413" left="306" width="243" height="8" font="font0" id="p1_t83" reading_order_no="102" segment_no="9" tag_type="text">examination by oil-immersion light microscopy, detection of</text>
<text top="423" left="306" width="243" height="9" font="font0" id="p1_t84" reading_order_no="103" segment_no="9" tag_type="text">asexual parasitemia of . 0 parasites/ l L resulted in the</text>
<text top="435" left="306" width="147" height="8" font="font0" id="p1_t85" reading_order_no="104" segment_no="9" tag_type="text">diagnosis and treatment for malaria.</text>
<text top="446" left="315" width="234" height="8" font="font5" id="p1_t86" reading_order_no="105" segment_no="11" tag_type="text">Assessment of secondary endpoints (humoral responses).</text>
<text top="457" left="306" width="243" height="8" font="font0" id="p1_t87" reading_order_no="106" segment_no="11" tag_type="text">Immunology samples were collected on study days 0, 14, 30, 44,</text>
<text top="468" left="306" width="243" height="8" font="font0" id="p1_t88" reading_order_no="107" segment_no="11" tag_type="text">60, 74, 90, 180, 270, and 364; samples collected on study days 0,</text>
<text top="479" left="306" width="243" height="8" font="font0" id="p1_t89" reading_order_no="108" segment_no="11" tag_type="text">30, and 60 were collected immediately prior to vaccination.</text>
<text top="490" left="306" width="243" height="8" font="font0" id="p1_t90" reading_order_no="109" segment_no="11" tag_type="text">Immune response to the FMP1/AS02A vaccine was determined</text>
<text top="501" left="306" width="243" height="8" font="font0" id="p1_t91" reading_order_no="110" segment_no="11" tag_type="text">by anti-FMP1 ELISA endpoint titers reported in optical</text>
<text top="512" left="306" width="243" height="8" font="font0" id="p1_t92" reading_order_no="111" segment_no="11" tag_type="text">density units (ODUs), the dilution yielding an ODU of 1.0 in</text>
<text top="523" left="306" width="243" height="8" font="font0" id="p1_t93" reading_order_no="112" segment_no="11" tag_type="text">our assay. This assay has been described in detail elsewhere [22].</text>
<text top="541" left="306" width="55" height="10" font="font3" id="p1_t94" reading_order_no="113" segment_no="13" tag_type="title">Sample Size</text>
<text top="553" left="306" width="243" height="8" font="font0" id="p1_t95" reading_order_no="114" segment_no="15" tag_type="text">This trial represents the ﬁrst time to our knowledge that this</text>
<text top="564" left="306" width="243" height="8" font="font0" id="p1_t96" reading_order_no="115" segment_no="15" tag_type="text">vaccine candidate has been evaluated in a pediatric pop-</text>
<text top="575" left="306" width="243" height="8" font="font0" id="p1_t97" reading_order_no="116" segment_no="15" tag_type="text">ulation. Sample size was chosen after weighing the need to</text>
<text top="586" left="306" width="243" height="8" font="font0" id="p1_t98" reading_order_no="117" segment_no="15" tag_type="text">detect any possible vaccine associated AEs against the need to</text>
<text top="597" left="306" width="243" height="8" font="font0" id="p1_t99" reading_order_no="118" segment_no="15" tag_type="text">limit the number of subjects exposed to an investigational</text>
<text top="608" left="306" width="243" height="9" font="font0" id="p1_t100" reading_order_no="119" segment_no="15" tag_type="text">product. Incorporation of the Imovax t Rabies vaccine</text>
<text top="619" left="306" width="243" height="8" font="font0" id="p1_t101" reading_order_no="120" segment_no="15" tag_type="text">comparison group enabled broad initial estimates of the</text>
<text top="630" left="306" width="243" height="8" font="font0" id="p1_t102" reading_order_no="121" segment_no="15" tag_type="text">incidence of local and general side effects in a population</text>
<text top="641" left="306" width="243" height="8" font="font0" id="p1_t103" reading_order_no="122" segment_no="15" tag_type="text">that suffers from signiﬁcant comorbidity from exposure to</text>
<text top="652" left="306" width="243" height="8" font="font0" id="p1_t104" reading_order_no="123" segment_no="15" tag_type="text">endemic illnesses. The control cohort also served as a</text>
<text top="664" left="306" width="243" height="8" font="font0" id="p1_t105" reading_order_no="124" segment_no="15" tag_type="text">comparator for the longitudinal immune responses to the</text>
<text top="675" left="306" width="243" height="8" font="font0" id="p1_t106" reading_order_no="125" segment_no="15" tag_type="text">FMP1 antigen in a malaria-exposed population. Although</text>
<text top="686" left="306" width="243" height="8" font="font0" id="p1_t107" reading_order_no="126" segment_no="15" tag_type="text">comparative statistics for the safety variables were calculated,</text>
<text top="697" left="306" width="243" height="8" font="font0" id="p1_t108" reading_order_no="127" segment_no="15" tag_type="text">the study had low power to detect anything other than large</text>
<text top="708" left="306" width="243" height="8" font="font0" id="p1_t109" reading_order_no="128" segment_no="15" tag_type="text">differences in the incidence of local and general side effects</text>
<text top="719" left="306" width="129" height="8" font="font0" id="p1_t110" reading_order_no="129" segment_no="15" tag_type="text">between the vaccination groups.</text>
<text top="78" left="48" width="240" height="8" font="font9" id="p1_t111" reading_order_no="4" segment_no="4" tag_type="text">.......................................................................................</text>
<text top="59" left="54" width="228" height="8" font="font10" id="p1_t112" reading_order_no="2" segment_no="3" tag_type="title">Table 2. Timing of First, Second, and Third Vaccinations for</text>
<text top="70" left="54" width="155" height="8" font="font11" id="p1_t113" reading_order_no="3" segment_no="3" tag_type="title">Each Cohort (Dosage Group) over 12 wk</text>
<text top="95" left="54" width="24" height="7" font="font12" id="p1_t114" reading_order_no="5" segment_no="5" tag_type="table">Cohort</text>
<text top="95" left="95" width="193" height="7" font="font12" id="p1_t115" reading_order_no="6" segment_no="5" tag_type="table">Month 0 Month 1 Month 2 Month 3 Months 4–11</text>
<text top="117" left="54" width="83" height="6" font="font13" id="p1_t116" reading_order_no="7" segment_no="5" tag_type="table">10 l g/rabies Screening 1st</text>
<text top="117" left="166" width="11" height="6" font="font13" id="p1_t117" reading_order_no="8" segment_no="5" tag_type="table">2nd</text>
<text top="117" left="204" width="10" height="6" font="font13" id="p1_t118" reading_order_no="9" segment_no="5" tag_type="table">3rd</text>
<text top="117" left="241" width="41" height="6" font="font13" id="p1_t119" reading_order_no="10" segment_no="5" tag_type="table">SAE follow-up</text>
<text top="126" left="54" width="37" height="6" font="font13" id="p1_t120" reading_order_no="11" segment_no="5" tag_type="table">25 l g/rabies</text>
<text top="126" left="147" width="9" height="6" font="font13" id="p1_t121" reading_order_no="12" segment_no="5" tag_type="table">1st</text>
<text top="126" left="185" width="11" height="6" font="font13" id="p1_t122" reading_order_no="13" segment_no="5" tag_type="table">2nd</text>
<text top="126" left="223" width="10" height="6" font="font13" id="p1_t123" reading_order_no="14" segment_no="5" tag_type="table">3rd</text>
<text top="135" left="54" width="37" height="6" font="font13" id="p1_t124" reading_order_no="15" segment_no="5" tag_type="table">50 l g/rabies</text>
<text top="135" left="166" width="9" height="6" font="font13" id="p1_t125" reading_order_no="16" segment_no="5" tag_type="table">1st</text>
<text top="135" left="204" width="11" height="6" font="font13" id="p1_t126" reading_order_no="17" segment_no="5" tag_type="table">2nd</text>
<text top="135" left="241" width="10" height="6" font="font13" id="p1_t127" reading_order_no="18" segment_no="5" tag_type="table">3rd</text>
<text top="146" left="54" width="102" height="6" font="font15" id="p1_t128" reading_order_no="19" segment_no="7" tag_type="text">doi:10.1371/journal.pctr.0010032.t002</text>
<text top="47" left="45" width="2" height="105" font="font9" id="p1_t129" reading_order_no="1" segment_no="1" tag_type="figure">. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..</text>
<text top="742" left="45" width="85" height="7" font="font16" id="p1_t130" reading_order_no="130" segment_no="19" tag_type="text">www.plosclinicaltrials.org</text>
<text top="742" left="471" width="78" height="7" font="font16" id="p1_t131" reading_order_no="132" segment_no="20" tag_type="text">November | 2006 | e32</text>
<text top="742" left="289" width="16" height="7" font="font16" id="p1_t132" reading_order_no="131" segment_no="21" tag_type="text">0004</text>
<text top="26" left="387" width="162" height="7" font="font16" id="p1_t133" reading_order_no="0" segment_no="0" tag_type="title">Pediatric MSP-1 Phase Ib Trial in Western Kenya</text>
</page>
</pdf2xml>
